Andrew Callos Sells 14,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Posted by Brenda Bartman on Aug 1st, 2026

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) EVP Andrew Callos sold 14,000 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total value of $1,118,320.00. Following the sale, the executive vice president directly owned 58,555 shares in the company, valued at approximately $4,677,373.40. The trade was a 19.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Callos also recently made the following trade(s):

On Wednesday, July 1st, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $85.80, for a total value of $1,287,000.00.
On Monday, June 1st, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $74.08, for a total value of $1,111,200.00.
On Friday, May 1st, Andrew Callos sold 15,857 shares of Cytokinetics stock. The stock was sold at an average price of $65.00, for a total transaction of $1,030,705.00.

Cytokinetics Trading Down 4.1%

Shares of NASDAQ CYTK opened at $77.13 on Friday. Cytokinetics, Incorporated has a twelve month low of $32.89 and a twelve month high of $88.31. The company has a market capitalization of $9.60 billion, a price-to-earnings ratio of -11.28 and a beta of 0.42. The firm has a 50-day moving average of $78.75 and a two-hundred day moving average of $70.39.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, meeting the consensus estimate of ($1.67). The business had revenue of $19.36 million for the quarter, compared to the consensus estimate of $8.52 million. During the same quarter last year, the business posted ($1.36) EPS. The business’s revenue for the quarter was up 1112.5% on a year-over-year basis. As a group, research analysts predict that Cytokinetics, Incorporated will post -6.2 earnings per share for the current year.

Analysts Set New Price Targets

CYTK has been the topic of several recent research reports. Morgan Stanley lifted their price target on shares of Cytokinetics from $90.00 to $103.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada cut their price objective on Cytokinetics from $119.00 to $117.00 and set an “outperform” rating for the company in a research report on Tuesday, July 7th. Wall Street Zen raised Cytokinetics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $102.00 target price on shares of Cytokinetics in a report on Wednesday, June 17th. Finally, Wells Fargo & Company boosted their target price on Cytokinetics from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.90.

Get Our Latest Report on CYTK

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC lifted its stake in Cytokinetics by 361.9% in the 1st quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company’s stock worth $11,571,000 after acquiring an additional 225,576 shares in the last quarter. Cetera Investment Advisers boosted its position in Cytokinetics by 12.4% during the 2nd quarter. Cetera Investment Advisers now owns 6,635 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 731 shares during the period. EverSource Wealth Advisors LLC grew its stake in Cytokinetics by 723.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 673 shares in the last quarter. Gabelli Funds LLC grew its stake in Cytokinetics by 29.4% during the 2nd quarter. Gabelli Funds LLC now owns 8,410 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 1,910 shares in the last quarter. Finally, California Public Employees Retirement System increased its holdings in shares of Cytokinetics by 10.8% in the 2nd quarter. California Public Employees Retirement System now owns 142,602 shares of the biopharmaceutical company’s stock valued at $4,712,000 after purchasing an additional 13,911 shares during the period.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: UK approval and reimbursement support: The Medicines and Healthcare products Regulatory Agency authorized MYQORZO® (aficamten) across the United Kingdom for eligible adults with symptomatic obstructive hypertrophic cardiomyopathy. NICE also recommended aficamten for use in England and Wales, potentially expanding access to roughly 6,600 NHS patients. Commercial availability is expected later this year, creating a potential new revenue stream. Cytokinetics wins UK approval, NICE backing for heart disease drug
Positive Sentiment: Encouraging clinical evidence: The UK decisions were supported by the phase 3 SEQUOIA-HCM trial, in which aficamten significantly improved peak oxygen uptake versus placebo. This strengthens the commercial case for the company’s lead cardiovascular drug. Cytokinetics announces MHRA authorization and NICE guidance
Positive Sentiment: Generally favorable analyst view: Brokerages maintain a consensus “Moderate Buy” rating, with a reported average price target near $99.90, above recent trading levels. Some firms have set targets between $105 and $118. Cytokinetics receives Moderate Buy consensus rating
Neutral Sentiment: Upcoming earnings catalyst: Analysts expect CYTK could exceed estimates in its upcoming second-quarter report. However, Cytokinetics remains unprofitable, and its prior quarter reported a loss of $1.67 per share despite revenue exceeding expectations. Cytokinetics earnings expectations
Negative Sentiment: Continued insider selling: EVP Andrew Callos sold 14,000 shares worth approximately $1.12 million, reducing his ownership by 19.3%. The sale was made under a pre-arranged Rule 10b5-1 plan, limiting its value as a discretionary bearish signal, but it follows a broader pattern of insider sales without reported purchases in recent months. SEC insider trading filing

About Cytokinetics

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.